Skip to content

Safety of long-term consumption of Tablets.

Safety of long-term consumption of Tablets. - Safety of long-term consumption of Tablets.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053276
Enrollment
20
Registered
2024-01-08
Start date
2024-01-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Consumption of Tablets, quantity of recommended daily intake, for 12 weeks.

Sponsors

EP Mediate Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy males and females from 20 to 64 years of age

Exclusion criteria

Exclusion criteria: (1) Subjects who are taking healthy foods related functional substance for at least one day a week at the start of this study (2) Subjects who have abnormalities in clinical examination values, cardiopulmonary function, or have a history of serious kidney or gastrointestinal diseases (3) Subjects who may develop allergies in relation to this study (4) Subjects who have a disease that requires constant medication (whether external or internal), those who have a disease under treatment (except for dry eye and dental caries treatment), those who have a history of serious disease that required medication (5) Subjects whose physical measurements, physical examination values, and clinical examination values before the start of intake were significantly out of the reference range (6) Subjects who work in shifts, work late at night, or have an irregular daily rhythm (7) Subjects who are participating in the other study within 1 month before the start of this study (8) Subjects who plan to become pregnant or breastfeed during the study period (9) Subjects who are judged to be unsuitable as subjects based on the answers to the background survey (10) Subjects who are judged as unsuitable for the study by the investigator for other reason

Design outcomes

Primary

MeasureTime frame
Hematologic test, Blood biochemistry test, Urine test, Blood pressure/pulsation, Weight/body mass index, Medical Interview, before and 4, 8,12 weeks after intake and Adverse events thorough the study

Countries

Japan

Contacts

Public ContactSaki Miyayama

EP Mediate Co., Ltd. R&D Support Center Foods Department

miyayama.saki392@eps.co.jp070-3023-8210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026